Venture
from24/7 Wall St.
12 hours agoIovance Surged 44% This Week and Its Philadelphia Factory Explains Why
Iovance Biotherapeutics transformed from a pipeline company to a profitable commercial entity with proprietary manufacturing capabilities, driving a 43% stock surge after Q4 2025 earnings.